Abstract: Novel pharmaceutical compositions are comprised of the salt or ion pair formation of a non-steroidal anti-inflammatory drug and an antihistamine or other decongestant. The physico-chemical characteristics of these compositions show them to be substantially different from their parent acid or base and will enable the preparation of dual action sustained or enhanced relief therapy regimens. The compositions also possessed enhanced stability and therefore the multi-symptom relief can be incorporated into a number of dosage forms such as capsules, tablets, elixirs, ointments and the like.

Abstract: A method for decreasing appetite for alcohol in humans which comprises the steps of providing an effective dosage of an alpha-2-adrenergic antagonist to the subject.

Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse.

Abstract: A method of producing analgesia and treating antiinflammatory disease in a human subject while avoiding proteinuria by administering 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide or a pharmaceutically-acceptable base salt thereof.

Abstract: A method for the treatment of dementia and cerebrovascular disorders and for inhibiting platelet aggregation in patients in need thereof comprising the step of administering a therapeutically effective amount of a 1-[3-(dimethylamino)propyl]-1-phenylphthalane of the general formula ##STR1## wherein R.sup.1 and R.sup.2 each are selected from the group consisting of halogen, trifluoromethyl, cyano and R--CO--, wherein R is an alkyl radical, or a pharmaceutically-acceptable acid addition salt thereof, is described.

Abstract: The invention relates to pharmaceutical compositions for peroral administration comprising (a) pharmaceutically useful methanediphosphonic acid derivatives, e.g. those of formula I ##STR1## wherein R.sub.1 and R.sub.2 are as defined in the specification, or pharmaceutically acceptable salts thereof, (b) specific macrocyclic polyethers and optionally (c) pharmaceutically acceptable adjuvants. The pharmaceutical compositions are prepared in a manner known per se. A method of treating hypercalcemia and osteolytic bone metastases with these compositions is also disclosed herein.

Abstract: A novel method for the prevention and control of epileptic seizures, particularly intractable seizures associated with the Lennox-Gastaut syndrome, employing pharmaceutical compositions containing 2-phenyl-1,3-propanediol dicarbamate.

Abstract: A method for improving primary memory or learning in a mammal comprising administering a 5-hydroxytryptamine receptor agonist which is selective for the 5-hydroxytryptamine-1A receptor subtype, or a pharmaceutically acceptable salt thereof.

Abstract: A novel use for the class of biologically active bis-indole alkaloid compounds, which have been named topsentins, nortopsentins, or dragmacidins, pharmaceutical compositions containing them, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-inflammatory properties exhibited by the bis-indole compounds and their analogs.

Abstract: This invention relates to a medication to treat addicts who are addicted to drugs or narcotics (including opium, morphine, heroine, cocaine, marijuana, amphetamine, etc.), the preparative method of this medication, as well as the treatment method for the addicts by using this medication. This medication to treat addiction is aconitane deivative having structures of formula I or II, wherein the formula I, R=.alpha.--OCH.sub.3, .beta.--OCH.sub.3 or .alpha.--OH; R.sub.1 =OAcABz, OH, OABz or H; R.sub.2 =H or OH; R.sub.3 =H or OH; R.sub.4 =H or OH; R.sub.5 =H or OH; R.sub.6 =OCH.sub.3, OBz, OAc or OH; wherein the formula II, R.sub.1 =R.sub.2 =R.sub.3 =OH.This medication to treat addiction is characterized by no drug-dependence, high cure effect, fast action and low side effect.

Abstract: The present invention relates to a method for desensitizing a subject animal, which comprises administering to the subject animal a therapeutically effective desensitizing amount of resiniferatoxin for desensitizing the subject animal to neurogenic inflammation, to chemically and thermally induced pain and to responses involving sensory afferent pathways sensitive to capsaicin and to responses involving the hypothalamic temperature control region, and a pharmaceutically acceptable carrier therefor.

Abstract: Flupirtine is used for the treatment of disorders involving skeletal muscle tension.

Abstract: The present invention relates to the use of inositoltrisphosphate (IP.sub.3) for the preparing of a medicament effective as a neuropeptide Y- (NPY-) antagonist and to a pharmaceutical composition comprising at least one specific isomer of IP.sub.3 and a pharmaceutically active compound effective in the cardiovascular, renal and/or cerebral area.

Abstract: This invention provides a method of preventing or treating hyperproliferative vascular disease in a mammal by administering an amount of mycophenolic acid effective to inhibit intimal thickening.

Abstract: There is disclosed a method for treating psychiatric disorders including circadian rhythm disorders, borderline personality disorders, personality disorders, Late Luteal Phase Dysphoric Disorder, psychoactive substance use disorders, sexual disorders, and schizophrenia and certain psychiatric symptoms including stress, anger, worry, rejection sensitivity and lack of mental or physical energy with administration of a nontoxic dose of a serotonin re-uptake blocker. Preferably, the serotonin re-uptake blocker is fluoxetine or norfluoxetine.

Abstract: Novel 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof having the formula ##STR1## wherein x is methylene or ethylene; R.sub.1 is dimethylamino, diethylamino, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, anilino or substituted anilino; R.sub.2 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; R.sub.3 is hydrogen, straight or branched alkyl of 1 to 9 carbon atoms, aryl or arylalkyl; and R.sub.4 is hydrogen, methyl, ethyl, allyl, benzyl, substituted benzyl, cyclopentyl, substituted cyclopentyl, cyclopenten-1-yl, or substituted cyclopenten-1-yl; and wherein aryl is phenyl or phenyl substituted with one or more methoxyl, hydroxyl, methylenedioxy, chloro, bromo, fluoro, ethoxycarbonylmethoxy, benzoxy, alkyl group, or their combination, possess anti-inflammatory, analgesic and anticancer properties.

Abstract: The treatment of neurodegenerative diseases by the stimulation of endogenous or recombinant expression in vivo of nerve growth factor in the central nervous system by administration of a therapeutically effective amount of an .alpha..sub.2 -antagonist.

Abstract: The present invention relates to methods of using and pharmaceutical compositions containing compounds of Formula I: ##STR1## wherein R.sup.1 is hydrogen, --COR.sup.4 wherein R.sup.4 is C.sub.1 -C.sub.4 alkyl, or --COOR.sup.5 wherein R.sup.5 is C.sub.1 -C.sub.4 alkyl; R.sup.2 is C.sub.1 -C.sub.4 alkyl, phenyl, or --OR.sup.6 wherein R.sup.6 is C.sub.1 -C.sub.4 alkyl; and R.sup.3 is C.sub.6 -C.sub.8 alkyl, halogen, or NO.sub.2 ; with the proviso that when R.sup.1 is hydrogen, R.sup.2 is C.sub.1 -C.sub.4 alkyl; and a pharmaceutically acceptable carrier. Compounds of Formula I and pharmaceutical compositions containing them are inhibitors of 5-lipoxygenase and are useful in the treatment of conditions mediated by leukotrienes such as inflammation, allergy, hypersensitivity reactions, and proliferative skin diseases such as psoriasis.

Abstract: A process is provided which is useful in alleviating inflammation of tendons and/or joints in a patient in need of such treatment. The process comprises administering a vasodilator to the inflamed tissue, either topically or by injection. Advantageously, the vasodilator is papaverine or a pharmaceutically acceptable salt thereof such as papaverine hydrochloride. Advantageously, the papaverine hydrochloride may be administered topically in a composition comprising a carrier. The carrier dissolves the papaverine hydrochloride and enables it to penetrate the skin and be absorbed into the inflamed tissue.

Abstract: The monamine oxidase inhibitor drug L-deprenyl (phenylisopropyl methyl propynyl amine) is safely and conveniently used for the treatment of mental depression in a formulation applied to the skin of the patient. In this way the danger of side reaction due to the consumption of foods containing tyramine (the cheese effect) is minimized. Unlike other monamine oxidase drugs, such as Parnate, L-deprenyl does not cause skin irritation when used in this way.